A B S T R A C T
Background. The assignment of human leucocyte antigens (HLAs) against which antibodies are detected as unacceptable antigens (UAGs) avoids allocation of HLA-incompatible allografts. There is uncertainty as to what extent UAGs decrease the probability of receiving a kidney offer. Methods. Kidney transplantations in 3264 patients on the waiting lists of six German transplant centres were evaluated for a period of at least 2 years. The proportion of excluded offers due to UAGs was calculated as virtual panel-reactive antibodies (vPRAs). Results. In the common Eurotransplant Kidney Allocation Scheme, the transplant probability was unaffected by vPRAs in exploratory univariate analyses. In the multivariable model, a 1% increase in vPRA values was outweighed by an additional waiting time of 2.5 weeks. The model was confirmed using an external validation cohort of 1521 patients from seven centres. If only patients with standard risk were considered (e.g. no simultaneous transplantation of other organs), only 1.3 weeks additional waiting time was needed. In the Eurotransplant Senior Program, patients with vPRA values >50% had a strongly reduced transplant probability in the unadjusted analyses. In the multivariable model, a 1% increase in vPRA values was outweighed by an additional waiting time of 5 weeks. Conclusions: This study demonstrates that the assignment of UAGs decreases the transplant probability in both main Eurotransplant allocation programs because of insufficient compensatory mechanisms. At present, for immunized patients, a prolonged waiting time has to be weighed against the increased immunologic risk due to donor-specific antibodies not assigned as UAGs.
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I N T R O D U C T I O N
Antibodies against human leucocyte antigens (HLA) are a wellknown risk factor in kidney transplantation. To prevent allocation of HLA-incompatible allografts in the Eurotransplant region, 'unacceptable antigens' (UAGs) can be assigned. Organs are only offered to recipients for whom no donor antigen is registered as a UAG.
The definition of UAGs varies widely. Although all centres assign current specificities detected by the complement-dependent cytotoxicity (CDC) assay, there is still uncertainty concerning antibodies detected by sensitive methods. Consideration of weak antibodies could lower the immunological risk, but concurrently diminish the chance for organ offers and prolong waiting time. The proportion of excluded offers due to UAGs is referred to as virtual panel-reactive antibodies (vPRAs), and equals the percentage of donors positive for any UAG of a patient.
Within Eurotransplant, three kidney allocation schemes exist:
The Eurotransplant Kidney Allocation Scheme (ETKAS)
for organs from donors <65 years old [1] . All organs initially go through the acceptable mismatch (AM) algorithm (see below), where a recipient is found in $3% of cases [2] . 2. The Eurotransplant Senior Program (ESP) for organs from donors !65 years old [3] . Patients !65 years old must choose between ESP and ETKAS. For this decision, a shorter waiting time in ESP is weighed against the potentially poorer organ quality due to increased donor age. 3. The Eurotransplant AM Program for highly immunized patients [2] . Once accepted, a patient stays in AM irrespective of his current antibody status.
Further details and a comparison of allocation schemes from Eurotransplant and the United Network for Organ Sharing (UNOS) are summarized in Table 1 .
Although the recipient's immunization is irrelevant in kidney allocation in ESP and AM (here it only defines entry criteria), it is considered in ETKAS in the calculation of the mismatch probability score (MMP). For historical reasons, the panel reactivity of HLA antibodies in the most recent screening (recent PRAs) is used instead of vPRAs. As the screening test might vary from quarter to quarter and between centres, MMP is not only dependent on the recipient's immunization, but also on the most recently used method (like CDC, enzyme-linked immunosorbent assay or single antigen). Furthermore, MMP is strongly influenced by the frequency of the patient's HLA alleles. In patients with rare alleles, MMP reaches its maximum irrespective of the patient's immunization (see Supplementary Materials for details).
Due to these constraints, the compensation for missed organ offers due to UAGs in both ETKAS and ESP is probably incomplete. Therefore, we conducted this retrospective study to quantify the influence of UAGs on the probability of receiving a deceased donor kidney transplant.
M A T E R I A L S A N D M E T H O D S

Patients
All patients awaiting kidney transplantation in 2012 from six German transplant centres (Berlin, Bochum, Essen, Kiel, Lübeck and Münster) were included in the principal cohort. After performance of descriptive statistics and development of multivariable predictive models, further centres provided data for the validation cohort (Augsburg, Bonn, Düsseldorf, Köln-Lindenthal, Köln-Merheim, München-Großhadern and München-Rechts-der-Isar). The study was approved by the ethics committee of the University of Lübeck.
Data collection
UAGs assigned in 2012 and other parameters influencing transplant probability were retrieved from K_X_008 reports drawn from the Eurotransplant database ENIS. The follow-up time was at least 2 years or until kidney transplantation (median 2.3 years). Kidney transplantations were evaluated using the ENIS K_X_002 report.
UAGs assigned at the end of the observation period were retrieved from ENIS, as well as participation in AM or the status 'not transplantable'. vPRA values were calculated using the Eurotransplant virtual PRA calculator (http://www.etrl.org/ Virtual%20PRA/Default.aspx (4 January 2017, date last accessed)).
Statistical analyses
For descriptive statistics, patients from the principal cohort were grouped according to their vPRAs: <6%, 6-50%, 51-84% and !85%. Exploratory comparisons between groups for univariate predictors of outcome were performed by Pearson's chisqure-test, Mood's median test and log-rank analyses of Kaplan-Meier curves where appropriate.
U n a c c e p t a b l e H L A a n t i g e n s a n d w a i t i n g t i m e
Multivariable Cox regression models were developed for the following groups of patients:
1. ETKAS patients: <65 years old and not included in AM (neither at the start nor accepted during the study).
Patients were censored at the age of 65 years. 2. ESP patients: !65 years old, registered in ESP both at the start and at the end of observation, not included in AM.
In the case of living donation, patients were censored on the day of transplantation. For ETKAS, only data from the principal cohort were used to develop models. Data from the validation cohort were used to validate the final multivariable model. Due to the small number of ESP patients, patients from both the principal and the validation cohort were used for model development. No validation cohort was available.
Multivariable predictive models were developed using Cox regression modelling with variable selection in a stepwise procedure. Variables were retained if the corresponding P-value was <0.05. For ETKAS, only main effects of the variables age, sex, ABO blood group, waiting time, age at first dialysis <18 years, previous or simultaneous pancreas transplantation, history of or awaiting transplantation of other solid organs, patient considered 'not transplantable' at the beginning of the Calculation of MMP from recent PRAs contributes up to 100 match points depending on the mismatch probability for 1 zero or 1 broad HLA-A, -B or split DR mismatch, recent PRAs and probability for an ABO match based on 1000 kidneys offered CPRAs to match points conversion table, increased match points are added to the kidney allocation points for patients with CPRAs >80%. U n a c c e p t a b l e H L A a n t i g e n s a n d w a i t i n g t i m e A further model was developed for a more homogeneous subgroup of ETKAS patients from the principal cohort with 'standard risk'. The following patients were excluded:
• Age at first dialysis <18 years (prioritized kidney allocation for children) For ESP, only main effects of the variables age, sex, ABO blood group, waiting time, patient considered 'not transplantable' at the beginning of the observation period and vPRAs were investigated.
The decrease in transplantation risk due to increased vPRA was calculated according to the formula 100% *(1Àe vPRA_Difference * vPRA_Estimate ). The additional waiting time needed to outweigh a decreased transplantation risk due to vPRAs was calculated as follows: (ÀvPRA_Difference * vPRA_ Estimate)/(waiting_time_Estimate).
Validation of the prognostic model was performed by four methods [4] : (i) we estimated the regression coefficient on the prognostic index in the validation data for discrimination and model fit; (ii) the model misspecification/fit was checked; (iii) Harrell's c index and Gönen and Heller's K as measures of discrimination were calculated in the principle and validation
Analyses were performed using R version 3.1.2 R Foundation for Statistical Computing, Vienna, Austria, http:// www.R-project.org (4 January 2017, date last accessed)).
R E S U L T S
Characteristics of patients
A total of 3264 patients belonged to the principal cohort (characteristics shown in Table 2 ). Patients with higher vPRAs were younger and were more likely to be female or to have been transplanted previously. The distribution of vPRAs differed widely between centres (Figure 1 
Exploratory univariate analyses
Evaluating all patients from the principal cohort, the transplant probability was independent from the patients' vPRAs (Table 2) , whereas Kaplan-Meier curves showed a slightly reduced transplant rate in patients with vPRAs >50% (Figure 2A ). Comparing the allocation programs, patients were transplanted faster in ESP than in ETKAS ( Figure 2B ; descriptive P < 0.001).
Within ETKAS, sensitized patients had roughly similar transplant rates than non-immunized recipients ( Figure 2C ). Only in ESP were vPRAs >50% associated with a reduced transplant probability ( Figure 2D ; descriptive P < 0.05). In transplanted patients, the waiting time between first dialysis and transplantation was not prolonged in patients with high vPRAs (Figure 3) .
Consistency of vPRAs
Changes in vPRAs were rare; 91.5% of patients in the principal cohort belonged to the same vPRA category at the beginning and at the end of the observation period. Also, 5.9% of patients belonged to a higher vPRA category at the end of the observation period and only 2.6% to a lower vPRA category (Table 2) .
Predictive multivariable models in ETKAS patients
The first model included ABO blood group, age, waiting time, pancreas transplantation, patient considered 'not transplantable' at the start of observation and vPRAs (Table 3A) . As expected, waiting time at the start of observation and ABO blood group had a strong influence on the time until transplantation. A difference in vPRAs of, for example, 50% translates into a decreased transplantation risk of $30%. This risk could be outweighed by an additional waiting time of 2.5 weeks per 1% increase in vPRAs. organs, considered 'transplantable' at the start of observation, etc.). Here, the effect of patient age disappeared and waiting time had a stronger influence than for general ETKAS patients. A decreased transplantation risk due to a 1% increase in vPRAs could be outweighed by an additional waiting time of 1.3 weeks (Figure 4) .
Predictive multivariable models in ESP patients
For ESP, a similar model was obtained (Table 3D) . As no ESP patient was listed for simultaneous pancreas transplantation, and only one patient had a previous pancreas transplantation, this co-variable is missing in the ESP model. The effect of vPRAs is more pronounced than in ETKAS. A 1% increase of vPRAs was associated with a decreased transplantation risk of $1.4% (instead of 0.6% in ETKAS). A difference in vPRAs of 50% is translated into a decreased transplantation risk of $50%. This decreased risk could be outweighed by an additional waiting time of 5 weeks per 1% increase in vPRAs (Figure 4) .
Validation of the final predictive multivariable model in ETKAS patients
Patients from the validation cohort were more likely to belong to a higher vPRA category, and the vPRA category during the observation period changed more frequently (14 versus 8% of patients). Table 4 summarizes a comparison of further FIGURE 2: Probability of receiving a kidney transplant according to transplantation program (ETKAS, ESP, AM) and vPRAs. In unadjusted analyses from the principal cohort, the probability of receiving a kidney transplant was lower for patients with vPRAs !50% (A, descriptive P < 0.05). Patients were more likely to receive a kidney transplant in ESP than in ETKAS (B, descriptive P < 0.001). Patients with vPRAs !50% had a lower probability of transplantation in the ESP program (D, descriptive P < 0.05), but not in ETKAS (C, descriptive P ¼ 0.06). T0 represents the start of observation.
U n a c c e p t a b l e H L A a n t i g e n s a n d w a i t i n g t Table 3B .
D I S C U S S I O N
The impact of vPRA values due to UAGs on transplant probability was strongly dependent on the transplantation program and the patient population. An increase in vPRAs of 1% could be outweighed by an additional waiting time of 5 weeks for ESP patients, 2.5 weeks for general ETKAS patients and only 1.3 weeks for ETKAS patients with 'standard risk'.
The lower additional waiting time needed to compensate for an increased vPRAs in ETKAS patients with 'standard risk' suggests an interaction between vPRAs and some criteria defining the 'standard risk' population. The proportion of patients awaiting simultaneous pancreas-kidney transplantation, for example, was larger among non-immunized ETKAS patients. Simultaneously, the waiting time for combined pancreas-kidney transplantation is shorter than for kidney-only recipients [5] .
At first glance, vPRAs should have no influence in ESP, because UAGs are not taken into account in the allocation. In all evaluated centres, however, organ offers from donors with HLA antigens entered as UAGs had been declined, even in cases of negative crossmatches. The pronounced effect of vPRAs in ESP is presumably caused by the lack of compensatory benefits for immunized patients. Another reason might be a smaller donor pool due to only regional distribution of kidneys compared with the international allocation in ETKAS.
Even if the effect of vPRAs was significantly alleviated in ETKAS compared with ESP, it did not disappear. This is due to several characteristics of the compensatory factor MMP:
1. It is strongly influenced by the probability of receiving a kidney offer with few HLA mismatches. In patients with rare alleles, MMP reaches the maximum irrespective of the patient's immunization (see Supplementary Material for details). 2. MMP is limited to an advantage corresponding to an additional waiting time of 3 years. 3. MMP is calculated using recent PRAs instead of vPRAs.
If the recent testing had been performed by insensitive techniques, some HLA antibodies could be missing. Additionally, historical antibody specificities, or other specificities considered unacceptable for the next allograft (e.g. mismatches of previous allografts with early rejection), are included only in vPRAs. This leads to marked differences between vPRAs and recent PRAs. If the difference (vPRAsÀrecent PRAs) is maintained in model development for ETKAS patients, vPRAs no longer have a significant effect (data not shown). So replacing recent PRAs by vPRAs in the calculation of MMP (which Eurotransplant intends to implement) could eliminate the effect of vPRAs on waiting time.
A possible explanation for the negative effect of age in ETKAS might be a higher comorbidity of older patients, leading to more or longer intermittent periods of being considered 'not transplantable'. However, a significant effect of age on the time until transplantation could not be confirmed in the validation cohort.
In a Mexican study, patients with PRAs >20% had a higher risk of not receiving a kidney transplant [6] . This strong effect might be caused by the lack of compensatory mechanisms for immunized patients and a relatively small donor pool. Thus the results are comparable to the more pronounced reduction of the transplantation probability in ESP.
In a French study, a sufficient chance to get transplanted was calculated for all patients with CPRAs (similar to vPRAs) 85%, and even for 49% of patients with higher CPRAs [7] . All patients with CPRAs >85% had access to prioritized allocation. These results are comparable to our finding, that the probability of receiving a kidney transplant in the Eurotransplant prioritization program (AM) is similar to ETKAS ( Figure 2B ). Access to AM, however, is only possible for patients with mainly CDC-detectable antibodies. Therefore, the French data cannot be transferred to patients with high vPRAs and low CDC reactivity not accepted for AM. The median waiting time is given as a thick line within the boxes. The lower and upper borders of the boxes represent the 25th and 75th percentiles, respectively. The whiskers represent minimum and maximum values for the waiting time of transplanted patients. As there were only a few patients in AM with vPRAs <85%, or in ESP with vPRAs of 51-84%, only the median is given for these categories. In this unadjusted analysis, there were no visible differences between vPRA groups within each allocation scheme.
Recently, a large German transplant centre reported a significantly prolonged waiting time for transplanted patients with peak vPRAs >50% [8] , where 38% of transplantations in non-immunized patients but only 11% in patients with peak vPRAs !50% were living donations. As the waiting time with living donation usually is shorter than in deceased donor transplantation, the longer waiting time of patients with high peak vPRAs was caused, at least in part, by the reduced chance of finding a living donor. Therefore, a comparison with our multivariable model is not possible.
The strengths of the current study are the large study population, participation of multiple centres and validation of the multivariable model with data from further transplant centres for ETKAS, ensuring the generalizability of our findings. There are also some limitations:
1. The definition of UAGs and the methods for antibody detection were very heterogeneous between centres. However, this diversity should, not influence the results since the probability of receiving a kidney allograft is influenced by UAGs but not by the reason of why a UAG has been assigned. 2. The number of refused organ offers was unavailable.
Theoretically, the longer time to transplantation in immunized patients could partly be due to increased refusal of offered organs based on a combination of donor quality, HLA matching and donor-specific antibodies not entered as UAGs. In the participating centres, however, the patient's immunization beyond the official UAGs was not routinely considered in the decision whether to accept an organ. 3. In all programs, patients can temporarily be reported as 'not transplantable', excluding them from any organ offer. The models considered only whether patients were 'not transplantable' at the start of the observation period, but not for transient periods. 4. Patients could change the allocation scheme within the observation period. Patients !65 years of age could change between ETKAS and ESP at any time. It could only be determined to which allocation program a patient was assigned at the start and end of the observation period. In the ETKAS analysis, patients were censored at the age of 65 years, ensuring that all patients were listed in ETKAS during the whole study period.
Patients in ETKAS or ESP were allowed to enter AM if they fulfilled the inclusion criteria. To avoid confounding, patients enrolled in AM at the end of the observation period were excluded from the development of models for ETKAS and ESP. 5. Some data were not available for all patients. This was most pronounced for MMP, which was retrieved from database extracts drawn in 2012 and stored at the transplant centres. Due to a temporal malfunction of the algorithm generating the reports, MMP was unavailable for the largest centre of the principal cohort and therefore was not considered in model building.
According to the multivariable models, the effect of increased vPRAs equals, at most, between 2.5 years additional waiting time for ETKAS patients with 'standard risk' and 9.6 years in ESP (Figure 4 ). Obviously there must be an upper limit for the validity of this conclusion. If a patient has a rare HLA phenotype, and all other antigens are considered unacceptable, this patient will hardly ever get transplanted. Despite inclusion of 3264 patients in the principal cohort, the number of patients with high vPRAs was too low to calculate a reliable upper limit of validity for the model.
Recently the threshold for patients with a strongly reduced chance to be transplanted was estimated as the chance to get an organ offer being <2% [2] . Depending on the patient's blood group, this equals a vPRA value of 95-98%. Consequently, the upper limit for the validity of the multivariable model might be in the same range.
This study demonstrates that the effect of vPRAs on the transplant probability can be counteracted by a large donor pool and by compensatory mechanisms of the allocation scheme. However, these mechanisms in ETKAS are insufficient. MMP equals, at most, 100 points, which is $1/7 or less of the match points accumulating until organ allocation (see example in Table 1 ). In the UNOS-Organ Procurement and Transplantation Network algorithm, the additional allocation points for candidates with CPRAs >80% are much higher. This extensive prioritization of immunized patients led to an increase in transplants in the CPRA 99-100% category of >400% in the first year [9] .
Our retrospective study shows that UAGs diminish the transplantation probability and prolong the waiting time by between $1.3 weeks per percent vPRAs for ETKAS patients with 'standard risk' and 5 weeks per percent vPRAs in ESP. On the other hand, the median waiting time until transplantation is only $4 years in ESP, compared with 7 years in ETKAS (Figure 3) . Therefore, immunized older patients with short waiting times might initially profit from ESP, but change to ETKAS later if they still remain on the waiting list.
For all patients, the increased waiting time due to UAGs has to be weighed against the increased immunological risk due to HLA antibodies not taken into account in organ allocation. Ideally, the calculation of bonus points should be improved in ETKAS (and introduced in ESP) to achieve complete compensation for missed organ offers due to UAGs. Future studies should verify whether using vPRAs instead of recent PRAs in the calculation of MMP eliminates the influence of vPRAs on the transplant probability in ETKAS.
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